Evidence map›Paper›PMID 41799774›Full record

ArticleInternational journal of medical sciences2026

Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.

Fitria Sari Wulandari, Chih-Yang Wang, Dana R Crawford, Yung-Ning Yang, Chee-Kin Then, Sachin Kumar, Fat-Moon Suk, Lin-Yi Huang, Yu-Chen Sh Yang, Zi-Lin Li and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Fitria Sari WulandariGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Chih-Yang WangGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Dana R CrawfordDepartment of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA.
Yung-Ning YangDepartment of Pediatrics, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan.
Chee-Kin ThenDepartment of Radiation Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
Sachin KumarGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Fat-Moon SukDivision of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei 116, Taiwan.
Lin-Yi HuangDepartment of Pediatrics, E-DA Hospital, I-Shou University, Kaohsiung 82445, Taiwan.
Yu-Chen Sh YangJoint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan.
Zi-Lin LiGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Ya-Jung ShihGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Hoai Tran TuGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Kuan WangGraduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Hoang Dang PhuFaculty of Chemistry, University of Science, Ho Chi Minh City, Vietnam.
Chun-Mao LinDepartment of Biochemistry and Molecular Cell Biology, Taipei Medical University, Taipei, 110, Taiwan.
Do Thi Minh XuanFaculty of Pharmacy, Van Lang University, 69/68 Dang Thuy Tram Street, Ward 13, Binh Thanh District, Ho Chi Minh City 70000, Vietnam.
Dahlak Daniel SolomonGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Hung-Yun LinGraduate Institute of Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Jacqueline Whang-PengCancer Center, Wan Fang Hospital, Taipei Medical University, Taipei 11031, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell surface receptors play vital roles in cancer growth and metastasis. Integrin αvβ3 is overexpressed in various cancer cells and interacts with different growth factors to stimulate cancer progression. Thyroid hormone binds to αvβ3 to activate signal transduction and cell proliferation. However, thyroxine (T

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaIntegrin alphaVbeta3ThyroxineAnimalsCell Line, TumorCell ProliferationDoxorubicinEpidermal Growth FactorErbB ReceptorsGene Expression Regulation, NeoplasticHumansMiceMolecular Targeted TherapySignal TransductionXenograft Model Antitumor AssaysDoxorubicinEGFR protein, humanEpidermal Growth FactorErbB ReceptorsIntegrin alphaVbeta3Thyroxinecholangiocarcinomaepidermal growth factorepidermal growth factor receptor (EGFR)integrin αvβ3nano-tetracprogrammed death ligand 1 (PD-L1)thyroxine

Identifiers

PMID41799774
PMCPMC12964564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.